**Glycomic-Based Biomarkers for Ovarian Cancer: Advances and ...**
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8065431

April 01, 2021 - Ovarian cancer remains one of the most common causes of death among gynecological malignancies affecting women worldwide. Among the gynecological cancers, cervical and endometrial cancers confer the greatest burden to the developing and developed world, respectively; however, the overall survival rates for patients with ovarian cancer are worse than the two aforementioned.

**Brain Metastases from Ovarian Cancer: Current Evidence in ...**
https://www.mdpi.com/2072-6694/12/8/2156/htm

Based on present data, a multidisciplinary approach combining surgery, radiotherapy, and chemotherapy seem to be the best approach for patients with good performance status, although the median overall survival (>1 year) remains largely disappointing.

Cited by: 1  Author: Fulvio Borella, Luca Bertero, Antonio Moro...
Publish Year: 2020  Estimated Reading Time: 5 mins

### PEOPLE ALSO ASK

- Is the histopathology of epithelial ovarian cancer heterogeneous?
- Why is the death rate so high for ovarian cancer?
- What kind of genomic analysis is used to diagnose ovarian cancer?
- Which is a proposed model of ovarian tumorigenesis?
Brain Metastases from Ovarian Cancer: Current Evidence in ...
https://www.mdpi.com/2072-6694/12/8/2156
With this review, we provide the state of the art concerning brain metastases (BMs) from ovarian cancer (OC), a rare condition. Clinical, pathological, and molecular features, treatment options, and future perspectives are comprehensively discussed. Overall, a diagnosis of high-grade serous OC and an advanced disease stage are common features among patients who develop brain metastases.
Cited by: 1  Author: Fulvio Borella, Luca Bertero, Antonio Morro...
Published Year: 2020  Estimated Reading Time: 5 mins

Brain Metastases from Ovarian Cancer: Current Evidence in ...
https://www.mdpi.com/2072-6694/12/8/2156
With this review, we provide the state of the art concerning brain metastases (BMs) from ovarian cancer (OC), a rare condition. Clinical, pathological, and molecular features, treatment options, and future perspectives are comprehensively discussed. Overall, a diagnosis of high-grade serous OC and an advanced disease stage are common features among patients who develop brain metastases.
Cited by: 1  Author: Fulvio Borella, Luca Bertero, Antonio Morro...
Published Year: 2020  Estimated Reading Time: 3 mins

Redrawing the Lines: The Next Generation of Treatment in...
https://ascopubs.org/doi/full/10.1200/EDBK_237419
May 17, 2019 - Although not considered curative in nature, new therapeutic advances in metastatic breast cancer (MBC) have substantially improved patient outcomes. This article discusses the state-of-the-art and emerging therapeutic options for management of MBC. BC systemic therapy targets multiple key...
Name of Journal: World Journal of Hepatology
Manuscript NO: 66435
Manuscript Type: REVIEW

Addressing hepatic metastases in ovarian cancer: Recent advances in treatment algorithms and the need for a multidisciplinary approach

Hepatic metastases in ovarian cancer

Abstract
The lifetime risk for ovarian cancer incidence is 1.6% and the lifetime risk of death is 1.8%. Most ovarian cancer patients are diagnosed at advanced stages (FIGO) due to no distinct symptoms or existing preventive tests. Liver metastases have been found in up to 30% of patients dying of advanced-stage ovarian cancer. Recent studies suggest the need for a multidisciplinary approach, from initial diagnosis to oncologic surgery and chemotherapy treatments, mandating the involvement of Gynecologic Oncologists, Medical Oncologists, Surgeons, and Radiation Oncologists.
Addressing hepatic metastases in ovarian cancer: Recent advances

Brain Metastases from Ovarian Cancer: Current Evidence in ...
https://www.mdpi.com/2072-6694/12/8/2156
With this review, we provide the state of the art concerning brain metastases (BMs) from ovarian cancer (OC), a rare condition. Clinical, pathological, and molecular features, treatment options, and future perspectives are comprehensively discussed. Overall, a diagnosis of high-grade serous OC and an advanced disease stage are common features among patients who develop brain metastases.
Cited by: 1
Author: Fulvio Borrella, Luca Bertero, Antonio Morri...
Publish Year: 2020
Estimated Reading Time: 5 mins

Brain Metastases from Ovarian Cancer: Current Evidence in ...
https://www.mdpi.com/2072-6694/12/8/2156
With this review, we provide the state of the art concerning brain metastases (BMs) from ovarian cancer (OC), a rare condition. Clinical, pathological, and molecular features, treatment options, and future perspectives are comprehensively discussed. Overall, a diagnosis of high-grade serous OC and an advanced disease stage are common features among patients who develop brain metastases.
Cited by: 1
Author: Fulvio Borrella, Luca Bertero, Antonio Morri...
Publish Year: 2020
Estimated Reading Time: 3 mins

(PDF) Treatment of patients with peritoneal metastases ...
Despite recent advances in chemotherapy, outcomes of patients with peritoneal metastases (PM) from gastric cancer are still very poor and standard treatment has not been established.
Estimated Reading Time: 5 mins

Stereotactic Ablative Brachytherapy: Recent Advances in ...
https://www.mdpi.com/2072-6694/13/14/3493
Brachytherapy (BT), a type of focal anti-cancer radiotherapy, delivers a highly focused radiation dose to localized tumors, sparing surrounding normal tissues. Recent technological advances have helped to increase the accuracy of BT and, thus, improve BT-based cancer treatment. Stereotactic ablative brachytherapy (SABT) was designed to improve the ablative effect of radiation, which was ...
Author: Hui Xue, Bin Qiu, Hao Wang, Ping Jia...
Publish Year: 2021